Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date of Report: October 5, 2025
Event: Announcement of late-breaking, positive Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Findings
The filing details positive interim data from two Phase 1 trials: ARV-102-101 (healthy volunteers) and ARV-102-103 (patients with Parkinson's disease).
- Safety Profile:
- Healthy Volunteers: Well tolerated at single doses up to 200 mg and multiple daily doses up to 80 mg. No discontinuations due to adverse events (AEs) or serious adverse events (SAEs).
- Parkinson's Patients: Single doses of 50 mg and 200 mg were well tolerated. Only mild treatment-related AEs (headache, diarrhea, nausea) were observed; no SAEs occurred.
- Pharmacokinetics (PK): Exposure increased in a dose-dependent manner in both plasma and cerebrospinal fluid (CSF), confirming brain penetration in both populations.
- Pharmacodynamics (PD) and Biomarkers:
- Healthy Volunteers: Repeated daily doses ≥20 mg resulted in >90% reduction of LRRK2 protein in peripheral blood mononuclear cells (PBMCs) and >50% reduction in CSF. Reduced plasma phospho-Rab10T73 and urine bis(monoacylglycerol)phosphate (BMP) levels were observed.
- Parkinson's Patients: Median PBMC LRRK2 protein reductions were 86% (50 mg dose) and 97% (200 mg dose).
- CSF Proteomics: Unbiased analyses in healthy volunteers showed significant decreases in lysosomal pathway markers and neuroinflammatory microglial markers associated with LRRK2 variants.
Guidance, Outlook, and Risks
Management Commentary and Future Plans:
- The data supports intensified development of ARV-102 for Parkinson's disease and future studies for progressive supranuclear palsy (PSP).
- 2026 Timeline: The Company plans to present initial data from the multiple dose cohort of the Parkinson's Phase 1 trial (ARV-102-103) in 2026.
- Phase 1b Initiation: Pending multiple dose cohort data and Investigational New Drug (IND) clearance, the Company intends to initiate a Phase 1b trial in PSP patients in the first half of 2026.
Risks and Contingencies:
- The filing contains forward-looking statements regarding strategy, future operations, and trial timelines.
- Actual results may differ materially due to risks discussed in the Company's quarterly and annual reports.
- Future trial initiation is contingent upon data from the multiple dose cohort and regulatory clearance.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data not summarized in the 8-K.
- Monitor upcoming filings for the presentation of multiple dose cohort data from the Parkinson's Phase 1 trial (ARV-102-103) expected in 2026.
- Confirm the status of Investigational New Drug (IND) clearance required for the planned Phase 1b trial in progressive supranuclear palsy.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity, as this 8-K does not contain financial data.